Lyra Therapeutics (LYRA) Return on Equity (2021 - 2025)
Historic Return on Equity for Lyra Therapeutics (LYRA) over the last 5 years, with Q3 2025 value amounting to 24.35%.
- Lyra Therapeutics' Return on Equity rose 281300.0% to 24.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 24.35%, marking a year-over-year increase of 281300.0%. This contributed to the annual value of 1.85% for FY2024, which is 11100.0% down from last year.
- As of Q3 2025, Lyra Therapeutics' Return on Equity stood at 24.35%, which was up 281300.0% from 14.14% recorded in Q2 2025.
- In the past 5 years, Lyra Therapeutics' Return on Equity registered a high of 24.35% during Q3 2025, and its lowest value of 14.14% during Q2 2025.
- In the last 5 years, Lyra Therapeutics' Return on Equity had a median value of 0.82% in 2023 and averaged 1.25%.
- Data for Lyra Therapeutics' Return on Equity shows a peak YoY increase of 281300bps (in 2025) and a maximum YoY decrease of -122700bps (in 2025) over the last 5 years.
- Over the past 5 years, Lyra Therapeutics' Return on Equity (Quarter) stood at 1.07% in 2021, then soared by 40bps to 0.64% in 2022, then decreased by -14bps to 0.72% in 2023, then tumbled by -704bps to 5.8% in 2024, then skyrocketed by 520bps to 24.35% in 2025.
- Its last three reported values are 24.35% in Q3 2025, 14.14% for Q2 2025, and 10.28% during Q1 2025.